FAQ

Fibrous skin tumor of tuberous sclerosis

Known as: Facial angiofibromas, Adenoma sebaceum, facial angiofibroma 
Facial ANGIOFIBROMA in tuberous sclerosis
National Institutes of Health

Topic mentions per year

Topic mentions per year

1935-2018
051019352017

Related topics

Related topics

3 relations
Multiple Endocrine Neoplasia Type 1Sebaceous adenoma

Broader (1)

Tuberous Sclerosis

Related mentions per year

Related mentions per year

1936-2018
19401960198020002020
Fibrous skin tumor of tuberous sclerosis
Tuberous Sclerosis
Multiple Endocrine Neoplasia Type 1
Sebaceous adenoma

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Sun exposure causes somatic second-hit mutations and angiofibroma development in tuberous sclerosis complex.
Tuberous sclerosis complex (TSC) is characterized by the formation of tumors in multiple organs and is caused by germline… (More)
Is this relevant?
2012
2012
Topical Rapamycin Therapy to Alleviate the Cutaneous Manifestations of Tuberous Sclerosis Complex
BACKGROUND AND OBJECTIVES Facial angiofibromas are disfiguring facial lesions, present in up to 80% of patients with tuberous… (More)
  • table I
  • table II
  • figure 1
Is this relevant?
2012
2012
Sustained clinical effectiveness and favorable safety profile of topical sirolimus for tuberous sclerosis - associated facial angiofibroma.
BACKGROUND Tuberous sclerosis complex (TSC) is an autosomal dominant neurocutaneous disorder characterized by the development of… (More)
Is this relevant?
2012
2012
Facial angiofibromas treated with topical rapamycin: an excellent choice with fast response.
Tuberous sclerosis (TS) is the second most common genodermatosis in our country and one of its main characteristics is the… (More)
Is this relevant?
2012
2012
Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: a pilot study of four patients.
Tuberous sclerosis complex (TSC) is an autosomal dominant genodermatosis characterised by the development of hamartomatous… (More)
Is this relevant?
2012
2012
A novel application of topical rapamycin formulation, an inhibitor of mTOR, for patients with hypomelanotic macules in tuberous sclerosis complex.
T uberous sclerosis complex (TSC) is an autosomal dominant disease characterized by systemic hamartomas.Twogenes,TSCIandTSCII… (More)
Is this relevant?
2008
2008
The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis.
Tuberous sclerosis complex (TSC) is an autosomal dominant disorder with an incidence of approximately one in 6000. It arises from… (More)
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs.
Tuberous sclerosis (TSC) is a relatively common hamartoma syndrome caused by mutations in either of two genes, TSC1 and TSC2… (More)
Is this relevant?
1998
1998
Skin lesions in children with tuberous sclerosis complex: their prevalence, natural course, and diagnostic significance.
BACKGROUND Tuberous sclerosis complex (TSC) is an autosomal dominant disorder characterized by widespread cutaneous and visceral… (More)
Is this relevant?
1994
1994
Phenotypic characterisation of stellate and giant cells in giant cell fibroma by immunocytochemistry.
The origin of the stromal, stellate and multinucleate cells in oral giant cell fibroma is unclear. Sixteen giant cell fibromas… (More)
Is this relevant?